21 results on '"Boutros, Tanya"'
Search Results
2. Investigation of the impact of hepatic impairment on the pharmacokinetics of dacomitinib
3. Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers
4. Evaluation of Proton Pump Inhibitor Esomeprazole on Crizotinib Pharmacokinetics in Healthy Participants
5. Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects
6. The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers
7. A Phase I Open-Label Study to Investigate the Potential Drug–Drug Interaction Between Single-Dose Dacomitinib and Steady-State Paroxetine in Healthy Volunteers
8. Effect of Race and Sex on Single and Multiple Dose Pharmacokinetics of Desloratadine
9. Evaluation of Proton Pump Inhibitor Esomeprazole on Crizotinib Pharmacokinetics in Healthy Participants.
10. Effects of Renal Function on Crizotinib Pharmacokinetics: Dose Recommendations for Patients with ALK-Positive Non-Small Cell Lung Cancer
11. Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers
12. Abstract CT208: Absolute bioavailability of dacomitinib (PF-00299804): Comparison of oral and intravenous administration in healthy volunteers
13. Abstract LB-229: A phase 1 open-label fixed-sequence two-period crossover study of the effect of multiple doses of tamoxifen on palbociclib (PD-0332991) pharmacokinetics in healthy male volunteers
14. Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects
15. A phase I open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers
16. Influence of mild and moderate hepatic impairment on the pharmacokinetics (PK) of the pan-HER inhibitor dacomitinib.
17. Abstract 763: A phase 1 open-label study to investigate the potential drug-drug interaction (DDI) between single-dose (SD) dacomitinib (PF-00299804; DC) and steady-state (SS) paroxetine (PX) in healthy volunteers (HVs)
18. The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers
19. Pharmacokinetic interaction between ezetimibe and lovastatin in healthy volunteers*
20. Pharmacodynamic interaction between ezetimibe and rosuvastatin
21. Photolithography of self-assembled monolayers: optimization of protecting groups by an electroanalytical method
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.